[Experimental product testing of biomedicines].
作者信息
Vieths S, Seitz R
机构信息
Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland,
出版信息
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1131-2. doi: 10.1007/s00103-014-2029-x.
PMID:25200486
Abstract
摘要
相似文献
1
[Experimental product testing of biomedicines].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1131-2. doi: 10.1007/s00103-014-2029-x.
2
[Official experimental testing of biomedical products. Regulatory frame and importance of for quality, safety and efficacy].[生物医学产品的官方实验测试。监管框架及其对质量、安全性和有效性的重要性]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1133-8. doi: 10.1007/s00103-014-2028-y.
3
Current regulatory and scientific considerations for approving biosimilars in Iran.伊朗批准生物类似药的当前监管和科学考量
Biologicals. 2011 Sep;39(5):325-7. doi: 10.1016/j.biologicals.2011.06.019. Epub 2011 Aug 27.
4
[Regulatory aspects of biosimilars. Myths and facts].[生物类似药的监管方面。神话与事实]
Z Rheumatol. 2015 Oct;74(8):695-700. doi: 10.1007/s00393-014-1489-6.
5
[The network of official medicines control laboratories].[官方药品控制实验室网络]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Oct;57(10):1139-44. doi: 10.1007/s00103-014-2025-1.
6
7
Recent developments help the defense of drug companies in 10b-5 cases.近期的发展态势有助于制药公司在10b-5案件中的辩护。
Food Drug Law J. 1996;51(3):345-53.
8
Concept of biosimilar products in Jordan.约旦生物类似药产品的概念。
Biologicals. 2011 Sep;39(5):333-5. doi: 10.1016/j.biologicals.2011.06.013. Epub 2011 Aug 27.
9
Bolstering the FDA's drug-safety authority.加强美国食品药品监督管理局的药品安全监管权。
N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212.
10
[Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].[国家和欧洲机构对药品的批准——制药行业的后遗症]
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):596-600.
Zotero 插件